Logo image of ONC

BEIGENE LTD-ADR (ONC) Stock Fundamental Analysis

NASDAQ:ONC - Nasdaq - US07725L1026 - ADR

210.08  +4.74 (+2.31%)

After market: 210.08 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ONC. ONC was compared to 572 industry peers in the Biotechnology industry. ONC has a bad profitability rating. Also its financial health evaluation is rather negative. ONC is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ONC had negative earnings in the past year.
ONC had a negative operating cash flow in the past year.
ONC had negative earnings in each of the past 5 years.
In the past 5 years ONC always reported negative operating cash flow.
ONC Yearly Net Income VS EBIT VS OCF VS FCFONC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -2B -4B -6B -8B -10B

1.2 Ratios

The Return On Assets of ONC (-15.97%) is better than 81.77% of its industry peers.
The Return On Equity of ONC (-26.99%) is better than 80.89% of its industry peers.
Industry RankSector Rank
ROA -15.97%
ROE -26.99%
ROIC N/A
ROA(3y)-21.61%
ROA(5y)-31.52%
ROE(3y)-32.05%
ROE(5y)-48.63%
ROIC(3y)N/A
ROIC(5y)N/A
ONC Yearly ROA, ROE, ROICONC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of ONC (83.13%) is better than 87.79% of its industry peers.
ONC's Gross Margin has been stable in the last couple of years.
ONC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.09%
GM growth 5Y-0.25%
ONC Yearly Profit, Operating, Gross MarginsONC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -200 -400

More info and screens

3

2. Health

2.1 Basic Checks

ONC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ONC has more shares outstanding than it did 1 year ago.
ONC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ONC has a worse debt to assets ratio.
ONC Yearly Shares OutstandingONC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
ONC Yearly Total Debt VS Total AssetsONC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 10B 20B 30B 40B 50B

2.2 Solvency

An Altman-Z score of 4.11 indicates that ONC is not in any danger for bankruptcy at the moment.
ONC has a better Altman-Z score (4.11) than 78.76% of its industry peers.
A Debt/Equity ratio of 0.31 indicates that ONC is not too dependend on debt financing.
The Debt to Equity ratio of ONC (0.31) is worse than 70.97% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 4.11
ROIC/WACCN/A
WACC10.64%
ONC Yearly LT Debt VS Equity VS FCFONC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10B -10B 20B 30B

2.3 Liquidity

ONC has a Current Ratio of 1.94. This is a normal value and indicates that ONC is financially healthy and should not expect problems in meeting its short term obligations.
ONC's Current ratio of 1.94 is on the low side compared to the rest of the industry. ONC is outperformed by 76.64% of its industry peers.
A Quick Ratio of 1.72 indicates that ONC should not have too much problems paying its short term obligations.
The Quick ratio of ONC (1.72) is worse than 79.11% of its industry peers.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.72
ONC Yearly Current Assets VS Current LiabilitesONC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10B 20B 30B 40B

More info and screens

7

3. Growth

3.1 Past

The earnings per share for ONC have decreased strongly by -457.37% in the last year.
The Revenue has grown by 52.08% in the past year. This is a very strong growth!
ONC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 67.79% yearly.
EPS 1Y (TTM)-457.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-159.34%
Revenue 1Y (TTM)52.08%
Revenue growth 3Y101.8%
Revenue growth 5Y67.79%
Sales Q2Q%27.6%

3.2 Future

The Earnings Per Share is expected to grow by 77.27% on average over the next years. This is a very strong growth
ONC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.88% yearly.
EPS Next Y35.87%
EPS Next 2Y36.2%
EPS Next 3Y34.59%
EPS Next 5Y77.27%
Revenue Next Year52.03%
Revenue Next 2Y37.72%
Revenue Next 3Y30.68%
Revenue Next 5Y25.88%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ONC Yearly Revenue VS EstimatesONC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20B 40B 60B
ONC Yearly EPS VS EstimatesONC Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 500 1K 1.5K 2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ONC. In the last year negative earnings were reported.
Also next year ONC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONC Price Earnings VS Forward Price EarningsONC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONC Per share dataONC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

ONC's earnings are expected to grow with 34.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.2%
EPS Next 3Y34.59%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ONC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEIGENE LTD-ADR

NASDAQ:ONC (1/17/2025, 8:19:11 PM)

After market: 210.08 0 (0%)

210.08

+4.74 (+2.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners28.08%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap22.37B
Analysts81.82
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.1
Dividend Growth(5Y)N/A
DP-2.03%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-414.4%
Min EPS beat(2)-805.99%
Max EPS beat(2)-22.81%
EPS beat(4)0
Avg EPS beat(4)-490.89%
Min EPS beat(4)-999.2%
Max EPS beat(4)-22.81%
EPS beat(8)1
Avg EPS beat(8)-245.79%
EPS beat(12)2
Avg EPS beat(12)-169.29%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)14.14%
Min Revenue beat(2)0.26%
Max Revenue beat(2)28.03%
Revenue beat(4)4
Avg Revenue beat(4)14.41%
Min Revenue beat(4)0.26%
Max Revenue beat(4)28.03%
Revenue beat(8)8
Avg Revenue beat(8)17.43%
Revenue beat(12)11
Avg Revenue beat(12)13.57%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.92
P/FCF N/A
P/OCF N/A
P/B 6.78
P/tB 7.03
EV/EBITDA N/A
EPS(TTM)-49.45
EYN/A
EPS(NY)-1.18
Fwd EYN/A
FCF(TTM)-10.5
FCFYN/A
OCF(TTM)-5.42
OCFYN/A
SpS30.34
BVpS30.97
TBVpS29.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.97%
ROE -26.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.13%
FCFM N/A
ROA(3y)-21.61%
ROA(5y)-31.52%
ROE(3y)-32.05%
ROE(5y)-48.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.09%
GM growth 5Y-0.25%
F-Score4
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 16.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.72
Altman-Z 4.11
F-Score4
WACC10.64%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)25.9%
Cap/Sales(5y)29.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-457.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-159.34%
EPS Next Y35.87%
EPS Next 2Y36.2%
EPS Next 3Y34.59%
EPS Next 5Y77.27%
Revenue 1Y (TTM)52.08%
Revenue growth 3Y101.8%
Revenue growth 5Y67.79%
Sales Q2Q%27.6%
Revenue Next Year52.03%
Revenue Next 2Y37.72%
Revenue Next 3Y30.68%
Revenue Next 5Y25.88%
EBIT growth 1Y29.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.98%
EBIT Next 3Y32.29%
EBIT Next 5Y33.22%
FCF growth 1Y33.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.76%
OCF growth 3YN/A
OCF growth 5YN/A